intralesional bleomycin
PreclinicalSmall molecule
intralesional bleomycin is one of 16 small molecule programs targeting Keloid. It is currently in Preclinical.
1
Indications
2
Total Trials
1
Active Trials
15
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
15 competitors in Keloid
#DrugCompanyPhaseTrials
1Blenoxane
Bristol-Myers SquibbApproved
Kenalog
BBausch Health Americas, Inc.
Approved
Kenalog
BBassett Healthcare
Approved
Botox
RRevance Therapeutics, Inc.
Approved
Calan
VVal Adams
Approved
Decadron
AAspen Global Incorporated
Approved
Rapamune
PPrism Pharmaceuticals
Approved
Aldara
BBausch Health Americas, Inc.
Approved
Opzelura
PfizerPhase 2
Botulinum Toxin a
GSKPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for intralesional bleomycin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- SSophie Horbach